Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis

References

• NIH Consensus Development Panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001;285:785–95
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761–7
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Thompson DE, Cauley JA, et al Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:241–9
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468–73
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231–6
   PubMed Web of Science ®Google Scholar
• Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281–9
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673–84
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracutre risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118–24
   PubMed Web of Science ®Google Scholar
• Levis S, Quandt SA, Thompson D, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002;50:409–15
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Chesnut 3rd CH, Silverman SL, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000;109:267–76
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Johnston Jr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women: three-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444–50
   PubMed Web of Science ®Google Scholar
• Eviö S, Tiitinen A, Laitinen K, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004;89:626–31
   PubMed Web of Science ®Google Scholar
• Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, in women with postmenopausal osteoporosis. Am J Med 1998;104:219–26
   PubMed Web of Science ®Google Scholar
• Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000;85:720–6
   PubMed Web of Science ®Google Scholar
• Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985–92
   PubMed Web of Science ®Google Scholar
• Evista (raloxifene hydrochloride) Prescribing Information. Physicians' Desk Reference,56th ednMontvale, NJ: Medical Economics Company, Inc; 20021915–19
   Google Scholar
• Fosamax (alendronate sodium) Prescribing Information. Physicians' Desk Reference, 56th edn.Montvale, NJ: Medical Economics Company, Inc20022095–102
   Google Scholar
• Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial). Int J Intern Med 2004;255:503–11
   PubMed Web of Science ®Google Scholar
• Lufkin EG, Sarkar S, Kulkarni PM, et al. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rational for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin 2004;20:351–7
   PubMed Web of Science ®Google Scholar
• Luckey M, Kagan R, Greenspan S, et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004;11:405–15
   PubMed Web of Science ®Google Scholar
• Iwamoto J, Sato Y, Uzawa M, et al. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J 2008;49:119–28
   PubMed Web of Science ®Google Scholar
• Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86:1890–7
   PubMed Web of Science ®Google Scholar
• Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076–81
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in the incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586–92
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. Uncertain future of trials in osteoporosis. Osteoporosis Int 2002;13:443–9
   PubMed Web of Science ®Google Scholar
• Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 2005;80:379–88
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197–202
   PubMed Web of Science ®Google Scholar
• McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998;128:253–61
   PubMed Web of Science ®Google Scholar
• Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence? Mayo Clin Proc 2002;77:1031–43
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
   PubMed Web of Science ®Google Scholar
• Greendale GA, Wells B, Marcus R, Barrett-Connor E. How many women lose bone mineral density while taking hormone replacement therapy? Results from the postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 2000;160:3065–71
   PubMed Web of Science ®Google Scholar